Editorial: The brain-skin connection: Role of psychosocial factors and neuropeptides in psoriasis

Expert Review of Clinical Immunology

Volumn 5, Issue 6, 2009, Pages 623-627

  Chapman, Ben P ^a   Moynihan, Jan ^b  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^b UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CALCITONIN GENE RELATED PEPTIDE; CATECHOLAMINE; CORTICOTROPIN; CORTICOTROPIN RELEASING FACTOR; CYTOKINE; GLUCOCORTICOID; METHOXSALEN; NERVE GROWTH FACTOR; NEUROPEPTIDE; SUBSTANCE P; VASOACTIVE INTESTINAL POLYPEPTIDE;

ACUTE STRESS; ADAPTIVE IMMUNITY; ANXIETY; CHRONIC STRESS; DEPRESSION; EDITORIAL; GENDER; HUMAN; IMMUNOREGULATION; INNATE IMMUNITY; PATHOPHYSIOLOGY; PSORIASIS; PSYCHOLOGICAL ASPECT; PSYCHOTHERAPY; PUVA; RACE; RISK FACTOR; SOCIAL ASPECT;

EID: 77949860275     PISSN: 1744666X     EISSN: None     Source Type: Journal    
DOI: 10.1586/eci.09.56     Document Type: Editorial

References (52)

1. Kin NW, Sanders VM. It takes nerve to tell T and B cells what to do. J. Leukoc. Biol. 79(6), 1093-1104 (2006).
2. Glaser R, Kiecolt-Glaser JK. Stress-induced immune dysfunction: implications for health. Nat. Rev. Immunol. 5(3), 243-251 (2005).
3. Maes M, Song C, Lin A et al. The effects of psychological stress on humans: increased production of pro-inflammatory cytokines and a Th1-like response in stress-induced anxiety. Cytokine 10, 313-318 (1998).
4. Kiecolt-Glaser JK, Preacher KJ, MacCallum RC, Atkinson C, Malarkey WB, Glaser R. Chronic stress and age-related increases in the proinflammatory cytokine IL-6. Proc. Natl Acad. Sci. USA 100(15), 9090-9095 (2003).
5. Kavelaars A, Heijnen CJ. Stress, genetics, and immunity. Brain Behav. Immun. 20(4), 313-316 (2006).
6. Irwin MR, Miller AH. Depressive disorders and immunity: 20 years of progress and discovery. Brain Behav. Immun. 21(4), 374-383 (2007).
7. Hayley S, Poulter MO, Merali Z, Anisman H. The pathogenesis of clinical depression: stressor- and cytokineinduced alterations of neuroplasticity. Neuroscience 135(3), 659-678 (2005).
8. Anisman H, Merali Z, Poulter MO, Hayley S. Cytokines as a precipitant of depressive illness: animal and human studies. Curr. Pharm. Des. 11(8), 963-972 (2005).
9. Schiepers OJ, Wichers MC, Maes M. Cytokines and major depression. Prog. Neuropsychopharmacol. Biol. Psychiatry 29(2), 201-217 (2005).
10. Pace TW, Mletzko TC, Alagbe O et al. Increased stress-induced inflammatory responses in male patients with major depression and increased early life stress. Am. J. Psychiatry 163(9), 1630-1633 (2006).
11. Dantzer R, OConnor JC, Freund GG, Johnson RW, Kelley KW. From inflammation to sickness and depression: when the immune system subjugates the brain. Nat. Rev. Neurosci. 9(1), 46-56 (2008).
12. Bonaccorso S, Puzella A, Marino V et al. Immunotherapy with interferon-a in patients affected by chronic hepatitis C induces an intercorrelated stimulation of the cytokine network and an increase in depressive and anxiety symptoms. Psychiatry Res. 105(1-2), 45-55 (2001).
13. Maes M, Bonaccorso S. Lower activities of serum peptidases predict higher depressive and anxiety levels following interferon-a-based immunotherapy in patients with hepatitis C. Acta Psychiatr. Scand. 109(2), 126-131 (2004).
14. Marsland AL, Prather AA, Petersen KL, Cohen S, Manuck SB. Antagonistic characteristics are positively associated with inflammatory markers independently of trait negative emotionality. Brain Behav. Immun. 22(5), 753-761 (2008).
15. Chapman BP, Khan A, Harper M et al. Gender, race/ethnicity, personality, and interleukin-6 in urban primary care patients. Brain Behav. Immun. 23(5), 636-642 (2009).
16. Karlamangla AS, Singer BH, McEwen BS, Rowe JW, Seeman TE. Allostatic load as a predictor of functional decline. MacArthur studies of successful aging. J. Clin. Epidemiol. 55(7), 696-710 (2002).
17. Gruenewald TL, Seeman TE, Ryff CD, Karlamangla AS, Singer BH. Combinations of biomarkers predictive of later life mortality. Proc. Natl Acad. Sci. USA 103(38), 14158-14163 (2006).
18. Karlamangla AS, Singer BH, Seeman TE. Reduction in allostatic load in older adults is associated with lower all-cause mortality risk: MacArthur studies of successful aging. Psychosom. Med. 68(3), 500-507 (2006).
19. Valdimarsson H. The genetic basis of psoriasis. Clin. Dermatol. 25(6), 563-567 (2007).
20. van Beelen AJ, Teunissen MB, Kapsenberg ML, de Jong EC. Interleukin-17 in inflammatory skin disorders. Curr. Opin Allergy Clin. Immunol. 7(5), 374-381 (2007).
21. Zheng Y, Danilenko DM, Valdez P et al. Interleukin-22, a T(h)17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis. Nature 445(7128), 648-651 (2007).
22. Lowes MA, Kikuchi T, Fuentes-Duculan J et al. Psoriasis vulgaris lesions contain discrete populations of Th1 and Th17 T cells. J. Invest. Dermatol. 128(5), 1207-1211 (2008).
23. Korver JE, van Duijnhoven MW, Pasch MC, van Erp PE, van de Kerkhof PC. Assessment of epidermal subpopulations and proliferation in healthy skin, symptomless and lesional skin of spreading psoriasis. Br. J. Dermatol. 155(4), 688-694 (2006).
24. Vissers WH, Berends M, Muys L, van Erp PE, de Jong EM, van de Kerkhof PC. The effect of the combination of calcipotriol and betamethasone dipropionate versus both monotherapies on epidermal proliferation, keratinization and T-cell subsets in chronic plaque psoriasis. Exp. Dermatol. 13(2), 106-112 (2004).
25. Kourosh AS, Miner A, Menter A. Psoriasis as the marker of underlying systemic disease. Skin Ther. Lett. 13(1), 1-5 (2008).
26. Gottlieb AB, Chao C, Dann F. Psoriasis comorbidities. J. Dermatolog. Treat. 19(1), 5-21 (2008).
27. Gottlieb AB, Dann F, Menter A. Psoriasis and the metabolic syndrome. J. Drugs Dermatol. 7(6), 563-572 (2008).
28. Azfar RS, Gelfand JM. Psoriasis and metabolic disease: epidemiology and pathophysiology. Curr. Opin Rheumatol. 20(4), 416-422 (2008).
29. Urpe M, Buggiani G, Lotti T. Stress and psychoneuroimmunologic factors in dermatology. Dermatol. Clin. 23(4), 609-617 (2005).
30. Halevy S, Livni E. b-adrenergic blocking drugs and psoriasis: the role of an immunologic mechanism. J. Am. Acad. Dermatol. 29(3), 504-505 (1993).
31. Steinkraus V, Steinfath M, Stove L, Korner C, Abeck D, Mensing H. b-adrenergic receptors in psoriasis: evidence for down-regulation in lesional skin. Arch. Dermatol. Res. 285(5), 300-304 (1993).
32. Farber EM, Lanigan SW, Boer J. The role of cutaneous sensory nerves in the maintenance of psoriasis. Int. J. Dermatol. 29(6), 418-420 (1990).
33. Raychaudhuri SP, Farber EM, Raychaudhuri SK. Role of nerve growth factor in RANTES expression by keratinocytes. Acta Derm. Venereol. 80(4), 247-250 (2000).
34. Farber EM, Nall L. Psoriasis: a stressrelated disease. Cutis 51(5), 322-326 (1993).
35. Farber EM, Nickoloff BJ, Recht B, Fraki JE. Stress, symmetry, and psoriasis: possible role of neuropeptides. J. Am. Acad. Dermatol. 14(2 Pt 1), 305-311 (1986).
36. Nickoloff BJ, Schroder JM, von den DP et al. Is psoriasis a T-cell disease? Exp. Dermatol. 9(5), 359-375 (2000).
37. Raychaudhuri SP, Jiang WY, Smoller BR, Farber EM. Nerve growth factor and its receptor system in psoriasis. Br. J. Dermatol. 143(1), 198-200 (2000).
38. Aloe L, Alleva E, Fiore M. Stress and nerve growth factor: findings in animal models and humans. Pharmacol. Biochem. Behav. 73(1), 159-166 (2002).
39. Kimball AB, Jacobson C, Weiss S, Vreeland MG, Wu Y. The psychosocial burden of psoriasis. Am. J. Clin. Dermatol. 6(6), 383-392 (2005).
40. Richards HL, Fortune DG, Griffiths CE, Main CJ. The contribution of perceptions of stigmatisation to disability in patients with psoriasis. J. Psychosom. Res. 50(1), 11-15 (2001).
41. Hughes JE, Barraclough BM, Hamblin LG, White JE. Psychiatric symptoms in dermatology patients. Br. J. Psychiatry 143, 51-54 (1983).
42. Fortune D, Richards HL, Griffiths CE, Main CJ. Psychologic factors in psoriasis: consequences, mechanisms, and interventions. Dermatol. Clin. 23, 681-693 (2005).
43. Naldi L, Peli L, Parazzini F, Carrel CF. Family history of psoriasis, stressful life events, and recent infectious disease are risk factors for a first episode of acute guttate psoriasis: results of a case-control study. J. Am. Acad. Dermatol. 44(3), 433-438 (2001).
44. Fortune DG, Richards HL, Griffiths CE, Main CJ. Psychological stress, distress and disability in patients with psoriasis: consensus and variation in the contribution of illness perceptions, coping and alexithymia. Br. J. Clin. Psychol. 41(Pt 2), 157-174 (2002).
45. Arck PC, Slominski A, Theoharides TC, Peters EM, Paus R. Neuroimmunology of stress: skin takes center stage. J. Invest. Dermatol. 126(8), 1697-1704 (2006).
46. Harvima IT, Viinamaki H, Naukkarinen A et al. Association of cutaneous mast cells and sensory nerves with psychic stress in psoriasis. Psychother. Psychosom. 60(3-4), 168-176 (1993).
47. Joachim RA, Kuhlmei A, Dinh QT et al. Neuronal plasticity of the brain-skin connection: stress-triggered up-regulation of neuropeptides in dorsal root ganglia and skin via nerve growth factor-dependent pathways. J. Mol. Med. 85(12), 1369-1378 (2007).
48. Tausk F, Whitmore SE. A pilot study of hypnosis in the treatment of patients with psoriasis. Psychother. Psychosom. 68(4), 221-225 (1999).
49. Shenefelt PD. Biofeedback, cognitivebehavioral methods, and hypnosis in dermatology: is it all in your mind? Dermatol. Ther. 16(2), 114-122 (2003).
50. Fortune DG, Richards HL, Griffiths CE, Main CJ. Targeting cognitive-behaviour therapy to patients implicit model of psoriasis: results from a patient preference controlled trial. Br. J. Clin. Psychol. 43(Pt 1), 65-82 (2004).
51. Zachariae R, Oster H, Bjerring P, Kragballe K. Effects of psychologic intervention on psoriasis: a preliminary report. J. Am. Acad. Dermatol. 34(6), 1008-1015 (1996).
52. Kabat-Zinn J, Wheeler E, Light T et al. Influence of a mindfulness meditationbased stress reduction intervention on rates of skin clearing in patients with moderate to severe psoriasis undergoing phototherapy (UVB) and photochemotherapy (PUVA). Psychosom. Med. 60(5), 625-632 (1998).